HRMY - Harmony Biosciences Holdings, Inc.

29.36
-0.250   -0.851%

Share volume: 810,045
Last Updated: 04-28-2025
Pharmaceutical Products/Pharmaceutical Preparations: -0.10%

PREVIOUS CLOSE
CHG
CHG%
$29.61
-0.25
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
75%
Profitability 96%
Dept financing 37%
Liquidity 75%
Performance 64%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.24%
1 Month
-11.54%
3 Months
-24.37%
6 Months
-29.24%
1 Year
0.38%
2 Year
-10.38%
Key data
Stock price
$29.36
P/E Ratio 
13.48
DAY RANGE
$28.95 - $29.80
EPS 
$2.56
52 WEEK RANGE
$26.47 - $41.61
52 WEEK CHANGE
-$5.01
MARKET CAP 
1.962 B
YIELD 
N/A
SHARES OUTSTANDING 
56.835 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-29-2025
BETA 
1.35
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$592,723
AVERAGE 30 VOLUME 
$718,324
Company detail
CEO: John C.s Jacobs
Region: US
Website: harmonybiosciences.com
Employees: 200
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Harmony Biosciences Holdings, Inc. develops and commercializes therapies for patients with rare neurological disorders in the United States. WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

Recent news
loading